Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Apogee Therapeutics, Inc. | Director | Common Stock | 34.8K | $1.3M | $37.26 | Jul 13, 2023 | Direct |
Akili, Inc. | Director | Stock Option (Right to Buy) | 22K | May 2, 2023 | Direct | ||
Apogee Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 10.4K | Jun 5, 2024 | Direct | ||
Biohaven Pharmaceutical Holding Co Ltd. | CCO-Migraine & Common Disease | Common Shares | 0 | $148.50 | Oct 3, 2022 | Direct | |
Biohaven Pharmaceutical Holding Co Ltd. | CCO-Migraine & Common Disease | Restricted Share Unit Award | 0 | Oct 3, 2022 | Direct | ||
Biohaven Pharmaceutical Holding Co Ltd. | CCO-Migraine & Common Disease | Stock Options (Right to Buy) | 0 | Oct 3, 2022 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
APGE | Apogee Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
NAMS | NewAmsterdam Pharma Co N.V. | Apr 25, 2024 | 0 | $0 | 3 | May 3, 2024 | Chief Commercial Officer |
APGE | Apogee Therapeutics, Inc. | Jul 13, 2023 | 0 | $0 | 3/A | Jul 17, 2023 | Director |
AKLI | Akili, Inc. | May 2, 2023 | 1 | $0 | 4 | May 4, 2023 | Director |
AKLI | Akili, Inc. | Nov 2, 2022 | 1 | $0 | 4 | Nov 4, 2022 | Director |
BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Oct 3, 2022 | 12 | -$2.11M | 4 | Oct 3, 2022 | CCO-Migraine & Common Disease |
AKLI | Akili, Inc. | Aug 19, 2022 | 0 | $0 | 3 | Aug 19, 2022 | Director |
BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Jan 6, 2022 | 8 | -$486K | 4 | Jan 7, 2022 | CCO-Migraine & Common Disease |
BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Nov 25, 2021 | 3 | -$151K | 4 | Nov 26, 2021 | CCO-Migraine & Common Disease |